Results 61 to 70 of about 507,096 (126)

Immune Exhaustion in Chronic Infection and Cancer: Signaling Pathways and Therapeutic Interventions

MedComm, Volume 7, Issue 3, March 2026.
Immune exhaustion is a well‐established hallmark of both cancer and chronic infection. This review proposes a novel “infection–exhaustion–tumor axis” framework, wherein chronic pathogens (e.g., oncogenic viruses) evade immune surveillance by hijacking inflammatory signaling to drive immune cell exhaustion, thereby creating immunosuppressive niches ...
Yali Song, Yazhi Mo, Si Chen, Yuemei Chen, Chunying Zhang, Shanying Deng, Juan Liao, Yi He, Wei Wang, Weidong Zheng, Tingting Zeng   +10 more
wiley   +1 more source

Estado actual de la vacuna recombinante contra el virus del papiloma humano

Acta Médica Costarricense, 2008
La infección por el virus del papiloma humano (VPH) es una enfermedad de transmisión sexual común. Alrededor del mundo millones de personas están infectadas y el resto de la población en general tiene un riesgo de contraer la infección superior al 50 ...
Wendy Chan Acón, Lara Aguilar Morales, Carolina Soley, Adriano Arguedas Mohs   +3 more
doaj  

High‐Risk HPV in Men: A Hidden Threat to Public Health?

Reviews in Medical Virology, Volume 36, Issue 2, March 2026.
ABSTRACT High‐risk human papillomavirus (HR‐HPV) infection is a leading cause of several cancers, including those of the genital and oropharyngeal regions. While public health efforts have largely focused on women due to its link to cervical cancer, HPV also poses significant risks to men, particularly in the oropharyngeal regions. HR‐HPV prevalence in
Keesha L. Coker, Ethan L. Morgan
wiley   +1 more source

Vaccine Name Framing, Relationship Status, and Fear: Examining Heterosexual Men's Intention to Vaccinate Against Human Papillomavirus Infection

World Medical &Health Policy, Volume 18, Issue 1, March 2026.
ABSTRACT Against the backdrop of calling for nonfemale‐oriented promotion of vaccination against human papillomavirus (HPV), this study explored three potential names—“HPV Vaccine,” “Cervical Cancer Vaccine,” and “Genital Warts Vaccine”—to promote vaccination against HPV infection among heterosexual men.
Timothy K. F. Fung, Judy Yuen‐man Siu, Ho Man Leung   +2 more
wiley   +1 more source

HPV vaccination following cervical intraepithelial neoplasia grade 2 diagnosis and risk of progression

Acta Obstetricia et Gynecologica Scandinavica, Volume 105, Issue 2, Page 377-385, February 2026.
HPV vaccination in women undergoing active surveillance for CIN2 does not offer a protective effect against progression to CIN3+. Women should be informed that vaccination is not a substitute for clinical follow‐up and should be encouraged to adhere to recommended surveillance and treatment protocols Abstract Introduction Human papillomavirus (HPV ...
Dina O. Eriksen, Louise Krog, Eva B. Ostenfeld, Pernille T. Jensen, Kathrine D. Lycke, Therese K. Grønborg, Nicolas Wentzensen, Megan A. Clarke, Anne Hammer   +8 more
wiley   +1 more source

Nuevas perspectivas para la prevención del cáncer de cuello uterino basadas en el virus del papiloma humano

Biomédica: revista del Instituto Nacional de Salud, 2006
El cáncer de cuello uterino es el segundo más frecuente en mujeres y una de las causas más importantes de años perdidos de vida potencial, toda vez que afecta una gran proporción de mujeres jóvenes y de edad media.
Nubia Muñoz
doaj   +1 more source

Acceptance of HPV Vaccination: A Systematic Review of Knowledge, Attitudes and Barriers Among Healthcare Practitioners in Low‐ and Middle‐Income Countries

BioMed Research International, Volume 2026, Issue 1, 2026.
Background Cervical cancer is one of the diseases that reflects global inequities. Vaccination against the human papillomavirus (HPV) is one of the main pillars of the World Health Organization (WHO) 2030 cervical cancer 90:70:90 elimination strategy. The role of healthcare practitioners in HPV vaccination acceptance cannot be overemphasized.
Nancy Innocentia Ebu Enyan, Mengying Zhang, Sebastian Ken-Amoah, Michelle King-Okoye, Joyce Agyeiwaa, Richard Sarfo-Walters, Dorothy Addo-Mensah, Patrick Kafui Akakpo, Dorcas Obiri-Yeboah, Lawrence Doi, Cassiano Gonçalves-de-Albuquerque   +10 more
wiley   +1 more source

Antibody avidity measurements in recipients of Cervarix® vaccine following a two-dose schedule or a three-dose schedule [PDF]

, 2014
The HPV-16/18 vaccine (Cervarix®) is a prophylactic vaccine for the prevention of cervical cancer and contains recombinant virus-like particles (VLPs) assembled from the L1 major capsid proteins of human papillomavirus (HPV) strains 16 and 18. Although a
Lockman, Laurence, Giannini, Sandra L., Fochesato, Michel, Boxus, Mathieu, Thomas, Florence, Lorin, Clarisse   +5 more
core   +1 more source

Jämförelse av antigenicitet och biverkningsprofil mellan Gardasil och Cervarix

, 2017
Syftet var att undersöka vilket av vaccinen mot Humant papillomvirus-HPV, Gardasil eller Cervarix som är att föredra, med avseende på biverkningsprofilen, det vill säga vilket av vaccinen som är mest skonsamt för kroppen.
Geraldsson, Amanda
core   +3 more sources

Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.

, 2014
Aim of this investigator-initiated study was to evaluate and compare the titres of neutralizing and cross-neutralizing antibodies (NAbs) induced by the bivalent (Cervarix(®)) and quadrivalent (Gardasil(®)) HPV vaccines in a cohort of girls aged 11-13 ...
Squarzon, Laura, Squarzon L, PALU', GIORGIO, Pascucci, Maria Grazia, Gabrielli, Liliana, Pacenti M, Lazzarotto T, BARZON, LUISA, Gabrielli L, Pacenti, Monia, Masiero S, Palù, Giorgio, Pascucci MG, Marcati G, CAPUTO, ANTONELLA, Marcati, Giorgia, MANTELLI, BARBARA, Masiero, Serena, LAZZAROTTO, TIZIANA   +18 more
core   +1 more source